Ensysce biosciences receives notice from nasdaq

San diego, ca / accesswire / september 27, 2024 / ensysce biosciences, inc. (nasdaq:ensc) ("ensysce" or "company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, has received notice from the listing qualifications department staff of the nasdaq stock market ("nasdaq") stating that the company has not regained compliance with nasdaq listing rule 5550(a)(2) because the bid price for the company's common stock has remained below $1.00 per share through the initial 180-day compliance period ended september 23, 2024. the company is not eligible for a second 180-day period because it does not comply with the minimum stockholders' equity requirement for initial listing on the nasdaq capital market.
NDAQ Ratings Summary
NDAQ Quant Ranking